Complete Versus Culprit only Revascularisation in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction: Incidence and Outcomes from the London Heart Attack Group.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
03 2020
Historique:
received: 25 03 2019
revised: 24 04 2019
accepted: 10 06 2019
pubmed: 23 7 2019
medline: 26 1 2021
entrez: 23 7 2019
Statut: ppublish

Résumé

Despite advances in technology, patients with Cardiogenic Shock (CS) presenting with ST-segment myocardial infarction (STEMI) still have a poor prognosis with high mortality rates. A large proportion of these patients have multi-vessel coronary artery disease, the treatment of which is still unclear. We aimed to assess the trends in management of CS patients with multi-vessel disease (MVD), particularly looking at the incidence and outcomes of complete revascularisation compared to culprit vessel only. We undertook an observational cohort study of 21,210 STEMI patients treated between 2005 and 2015 at the 8 Heart Attack Centres in London, UK. Patients' details were recorded prospectively into local databases using the British Cardiac Intervention Society (BCIS) PCI dataset. 1058 patients presented with CS and MVD. Primary outcome was all-cause mortality. Patients were followed-up for a median of 4.1 years (IQR range: 2.2-5.8 years). 497 (47.0%) patients underwent complete revascularisation during primary PCI for CS with stable rates seen over time. These patients were more likely to be male, hypertensive and more likely to have poor LV function compared to the culprit vessel intervention group. Although crude, in hospital major adverse cardiac events (MACE) rates were similar (40.8% vs. 36.0%, p = 0.558) between the two groups. Kaplan-Meier analysis demonstrated no significant differences in mortality rates between the two groups (53.8% complete revascularisation vs. 46.8% culprit vessel intervention, p = 0.252) during the follow-up period. After multivariate cox analysis (HR 0.69 95% CI (0.44-0.98)) and the use of propensity matching (HR: 0.81 95% CI: 0.62-0.97) complete revascularisation was associated with reduced mortality. A number of co-variates were included in the model, including age, gender, diabetes, hypertension, hypercholesterolaemia, previous PCI, previous MI, chronic renal failure, Anterior infarct, number of treated vessels, pre-procedure TIMI flow, procedural success and GP IIb/IIIA use. In a contemporary observational series of CS patients with MVD, complete revascularisation appears to be associated with better outcomes compared to culprit vessel only intervention. This supports on-going clinical trials in this area and provides further evidence of the association of complete revascularisation in STEMI with good outcomes.

Sections du résumé

BACKGROUND
Despite advances in technology, patients with Cardiogenic Shock (CS) presenting with ST-segment myocardial infarction (STEMI) still have a poor prognosis with high mortality rates. A large proportion of these patients have multi-vessel coronary artery disease, the treatment of which is still unclear. We aimed to assess the trends in management of CS patients with multi-vessel disease (MVD), particularly looking at the incidence and outcomes of complete revascularisation compared to culprit vessel only.
METHODS AND RESULTS
We undertook an observational cohort study of 21,210 STEMI patients treated between 2005 and 2015 at the 8 Heart Attack Centres in London, UK. Patients' details were recorded prospectively into local databases using the British Cardiac Intervention Society (BCIS) PCI dataset. 1058 patients presented with CS and MVD. Primary outcome was all-cause mortality. Patients were followed-up for a median of 4.1 years (IQR range: 2.2-5.8 years). 497 (47.0%) patients underwent complete revascularisation during primary PCI for CS with stable rates seen over time. These patients were more likely to be male, hypertensive and more likely to have poor LV function compared to the culprit vessel intervention group. Although crude, in hospital major adverse cardiac events (MACE) rates were similar (40.8% vs. 36.0%, p = 0.558) between the two groups. Kaplan-Meier analysis demonstrated no significant differences in mortality rates between the two groups (53.8% complete revascularisation vs. 46.8% culprit vessel intervention, p = 0.252) during the follow-up period. After multivariate cox analysis (HR 0.69 95% CI (0.44-0.98)) and the use of propensity matching (HR: 0.81 95% CI: 0.62-0.97) complete revascularisation was associated with reduced mortality. A number of co-variates were included in the model, including age, gender, diabetes, hypertension, hypercholesterolaemia, previous PCI, previous MI, chronic renal failure, Anterior infarct, number of treated vessels, pre-procedure TIMI flow, procedural success and GP IIb/IIIA use.
CONCLUSION
In a contemporary observational series of CS patients with MVD, complete revascularisation appears to be associated with better outcomes compared to culprit vessel only intervention. This supports on-going clinical trials in this area and provides further evidence of the association of complete revascularisation in STEMI with good outcomes.

Identifiants

pubmed: 31327710
pii: S1553-8389(19)30367-7
doi: 10.1016/j.carrev.2019.06.007
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

350-358

Subventions

Organisme : Department of Health
ID : DRF-2014-07-008
Pays : United Kingdom
Organisme : Department of Health
ID : PB-PG-1216-20028
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None declared from any of the authors.

Auteurs

Krishnaraj S Rathod (KS)

Barts Health NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.

Sudheer Koganti (S)

Barts Health NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.

Ajay K Jain (AK)

Barts Health NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.

Roby Rakhit (R)

Royal Free London NHS Foundation Trust, Pond Street, London, United Kingdom of Great Britain and Northern Ireland.

Miles C Dalby (MC)

Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Hill End Road, Middlesex, London, United Kingdom of Great Britain and Northern Ireland.

Tim Lockie (T)

Royal Free London NHS Foundation Trust, Pond Street, London, United Kingdom of Great Britain and Northern Ireland.

Sundeep Kalra (S)

Royal Free London NHS Foundation Trust, Pond Street, London, United Kingdom of Great Britain and Northern Ireland.

Iqbal S Malik (IS)

Imperial College Healthcare NHS Foundation Trust, Hammersmith Hospital, Du Cane Road, London, United Kingdom of Great Britain and Northern Ireland.

Charles J Knight (CJ)

Barts Health NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.

Mark Whitbread (M)

London Ambulance Service NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.

Anthony Mathur (A)

Barts Health NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.

Sam Firoozi (S)

St. George's Healthcare NHS Foundation Trust, St. George's Hospital, London, United Kingdom of Great Britain and Northern Ireland.

Richard Bogle (R)

St. George's Healthcare NHS Foundation Trust, St. George's Hospital, London, United Kingdom of Great Britain and Northern Ireland.

Simon Redwood (S)

St Thomas' NHS Foundation Trust, Guys & St. Thomas Hospital, Westminster Bridge Rd, London, United Kingdom of Great Britain and Northern Ireland.

Philip A MacCarthy (PA)

King's College Hospital, King's College Hospital NHS Foundation Trust, Denmark Hill, London, United Kingdom of Great Britain and Northern Ireland.

Alexander Sirker (A)

Barts Health NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.

Constantinos O'Mahony (C)

Barts Health NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.

Andrew Wragg (A)

Barts Health NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.

Daniel A Jones (DA)

Barts Health NHS Trust, London, United Kingdom of Great Britain and Northern Ireland. Electronic address: dan.jones@bartshealth.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH